Filing summary
Entity and period: The supplied filing is TRxADE HEALTH, INC.’s unaudited Form 10-Q for the quarter ended June 30, 2022 (ticker MEDS), not a filing identified as Scienture Holdings, Inc. This entity discrepancy should be resolved before relying on the summary.
Business context
TRxADE operates a pharmaceutical marketplace and wholesaling business, a community pharmacy, and telehealth and related technology businesses. In February 2022, it formed SOSRx, a pharmaceutical marketplace venture that it owns 51% of with Exchange Health. The filing reports results for the three and six months ended June 30, 2022, compared with the same periods in 2021.
Financial performance
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Revenue | $3.279 million | $1.898 million | $6.519 million | $4.951 million |
| Gross profit | $1.171 million | $0.841 million | $2.507 million | $2.225 million |
| Gross margin | 36% | 44% | 38% | 45% |
| Net loss | $1.112 million | $2.578 million | $2.078 million | $3.230 million |
| Net loss per share | $0.13 | $0.32 | $0.25 | $0.40 |
| Cash used in operating activities | — | $2.179 million | $1.401 million |
Quarterly revenue rose 72.7%; six-month revenue rose 31.7%. Growth was driven chiefly by Integra/Trxade Prime, while Community Specialty Pharmacy revenue declined. Gross profit increased, but margins contracted as wholesaling revenue and its associated cost of sales grew. Losses narrowed year over year, substantially because 2021 included a $1.225 million inventory-investment loss; the company remained unprofitable.
Financial position and liquidity
At June 30, 2022, cash was $962,227, down from $3.123 million at December 31, 2021. Working capital was $800,969, versus $3.448 million at year-end. Total assets were $5.672 million, total liabilities $3.868 million, and stockholders’ equity $1.805 million. The accumulated deficit was $18.3 million.
Six-month investing cash use was $257,172, primarily for capitalized software; financing cash provided was $275,875, including $550,000 from future-receivables funding, partly offset by distributions to a non-controlling interest. Management states that additional capital or debt financing is needed and that, without it, the company is unlikely to meet funding requirements over the next 12 months. The filing concludes that substantial doubt exists about the company’s ability to continue as a going concern.
Debt and funding arrangements include a $500,000 Exchange Health promissory note ($166,667 current and $333,333 long-term at June 30); a $550,000 recorded current liability under an agreement that sells $792,000 of future receivables, with an approximately 36% effective interest rate; and a supplier credit arrangement of up to $500,000 secured by substantially all company assets. The filing also reports lease liabilities. These arrangements add repayment, collateral, and cash-flow risk.
Material changes and management outlook
- Trxade Prime’s Q2 processed sales increased 435% year over year; unique buyers rose 135%, orders 330%, and units sold 713%. The core Trxade marketplace reported Q2 processed sales volume growth of 21% and registered-user growth of 8%.
- Management expects revenue growth from the Trxade and Trxade Prime platforms over the next 12 months, but provides no formal revenue or earnings guidance. It estimated general and administrative and working-capital requirements of approximately $7 million from July 2022 through June 2023.
- After quarter-end, the company reported annual salary and wage reductions of approximately $500,000 and other cost reductions. It also said it adjusted Trxade Prime pricing and freight practices to improve gross margins.
- The Board authorized exploration of strategic alternatives for Bonum Health, including a sale, spin-off, financing, combination, or wind-down; no final decision had been made. DelivMeds had no revenue, while approximately $280,000 of development costs was capitalized in the first half of 2022.
- The company recorded a $100,000 bad-debt recovery after receiving an initial payment under a settlement requiring GSG PPE and its owner to pay $743,000 in installments over 17 months. Other disclosed claims include unresolved glove-deposit litigation; the filing says timing and recoveries are uncertain. A separate $225,000 settlement was reached in the Jain litigation.
Risks, contingencies, and controls
- Going concern and financing: Limited cash, continuing operating losses, and projected funding needs make access to additional financing a material risk; equity financing could dilute shareholders.
- Listing: The company stated it was not in compliance with Nasdaq continued-listing standards because equity was below $2.5 million and it did not meet the cited alternative income test. Delisting could reduce share liquidity and hinder financing.
- Cyber incident: An email account was compromised in April 2022, leading to an unauthorized outgoing ACH payment discovered in May. The company reported approximately $123,000 in related one-time costs and expects insurance recovery; the filing does not establish the amount or timing of any recovery.
- Funding and collateral: The future-receivables agreement gives the funder a priority interest and could require payment of all future sales proceeds after default. The Masters credit arrangement is secured by substantially all assets and may be changed or suspended based on the supplier’s assessment of the company’s financial condition.
- Internal controls: Management concluded disclosure controls were ineffective and cited material weaknesses in written accounting/reporting procedures and period-end reporting controls. No material change in internal control over financial reporting was reported during the quarter.
- Other disclosed risks include pharmaceutical supply disruptions, regulatory and licensing requirements, competition, possible inventory losses, litigation, data security, and the uncertain prospects of telehealth and SOSRx. SOSRx earn-out payments of up to $400,000 were not accrued because management considered the milestones unlikely to be achieved as of June 30.
Important facts for investors to verify
- Confirm the issuer: the filing identifies TRxADE HEALTH, INC., whereas the request identifies Scienture Holdings, Inc.
- Review the company’s cash runway, financing plans, and the basis for its going-concern assessment; verify any financing obtained after June 30, 2022.
- Check Nasdaq compliance status and any subsequent listing notices or remedial actions.
- Review the full terms, effective cost, payment mechanics, and default provisions of the future-receivables funding and secured supplier-credit arrangements.
- Verify the actual loss and insurance recovery from the cyber incident, and progress on the GSG settlement and other litigation recoveries.
- Assess whether revenue growth can translate into improved gross margins and cash generation, given the year-over-year margin decline and operating cash use.